Pfizer’s Latest Clinical Study: A New Hope for Advanced Breast Cancer Treatment

Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.

Study Overview: Pfizer Inc. is conducting a Phase 3 clinical study titled An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator’s Choice of Therapy in Adult Participants With Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy. The study aims to assess the safety and effectiveness of PF-07248144 combined with fulvestrant in treating HR-positive, HER2-negative advanced or metastatic breast cancer that has progressed following previous treatment.

Intervention/Treatment: The study tests PF-07248144, a KAT6 inhibitor, in combination with fulvestrant, an endocrine therapy. This combination is intended to treat advanced breast cancer by targeting hormone receptor-positive and HER2-negative cancer cells.

Study Design: This interventional study employs a randomized, parallel assignment model without masking. Participants are divided into two groups: one receiving PF-07248144 with fulvestrant, and the other receiving everolimus with the investigator’s choice of endocrine therapy. The primary purpose is treatment-focused.

Study Timeline: The study began on July 3, 2025, with the latest update on August 12, 2025. These dates are crucial as they indicate the study’s progress and current recruitment status.

Market Implications: This study could significantly impact Pfizer’s stock performance and investor sentiment, especially if the results show positive outcomes for PF-07248144. It positions Pfizer competitively in the oncology market, particularly against other companies developing treatments for advanced breast cancer.

The study is currently recruiting, and further details are available on the ClinicalTrials portal.